This week was a good one for iron ore stocks with the price of the commodity touching $US160 per tonne ($211/tonne), Friday.

And cannabis shares also received a lift, so to speak, from moves to de-criminalise the herb after the UN took it off its list of narcotics which classed the herb as harmful.

Less successful this week, in share price terms, was a WA gold explorer Kaili Resources, and one of Australia’s three securities exchanges for share trading.

Meantime, the spoof online news site The Betoota Advocate had a funny take on the long wait for President Donald Trump’s concession speech after November’s presidential election.

Trump Finally Concedes 1983 America’s Cup Loss

‘In an unprecedented admission, Future Former President Trump has finally conceded that the 1983 America’s Cup was won by the creatively-named Australian yacht Australia II.’ said The Betoota Advocate.

Strictly speaking, President Trump does not have to say anything on the election, as the presidential election process is not concluded until the Electoral College meets.

Electors from each of the US’s 50 states vote for their choice of president and vice-president on December 14, and their votes are delivered to the US Senate by December 23.

On another note, here are the small caps that made good moves this week.

ASX SMALL CAP WINNERS

Sunshine Gold (ASX:SHN) +200% was a clear winner, making gains at the end of the trading week, after it rejoined the ASX as a gold exploration company.

The gold explorer has sloughed off its former name of Pelican Resources and was a former owner of the Cockatoo Island iron ore project in WA.

Sunshine Gold is led by managing director, Damien Keys, who led exploration teams at Black Cat Syndicate (ASX:BC8), Silver Lake Resources (ASX:SLR), and Gold Fields Australia.

It has two gold exploration projects in Queensland, Hodgkinson near Cairns, and Triumph south of Gladstone port at which it has started drilling.

As Pelican Resources the company recently sold its Romblon nickel project in the Philippines for $2.1m.

Creso Pharma (ASX:CPH) +160% on a series of positive news announcements during the week that set its share price racing like a greyhound.

The cannabis products company signed a deal with natural medicine supplier Martin & Pleasance, whose brands include Ener-C multivitamin drink mix; Schuessler Tissue Salts; He Men’s health; and Zen Joint & Pain relief. It sells to over 4,000 pharmacies across Australia and New Zealand.

The deal is contingent on the Therapeutic Goods Administration down-scheduling CBD products so they can be sold in pharmacies rather than via a doctor’s prescription. The TGA is expected to make a decision in late December.

On Wednesday, the company announced its expansion in Canada’s cannabis market with $288,000 of purchase orders from the Yukon Territory, and Ontario Province.

Earlier in the week, it said the US House of Representatives had passed the Marijuana Opportunity Reinvestment and Expungement Act to remove cannabis from the US Controlled Substances Act. The bill decriminalises many aspects of cannabis use in the US.

SI6 Metals (ASX:SI6) +140% as it posted mid-week a company update that said it had started drilling at its Maibele nickel-copper-cobalt-pge project in Botswana.

In WA, a program of works is being rolled out for its Monument gold project, and it has received commitments for a $2m share placement.

The share placement is priced at 1.7c per share and has attracted firm commitments from sophisticated, professional and other investors.

“With our ongoing drilling program at Botswana underway and our program of works approved to commence drilling at the Monument gold project in WA, we are thrilled that some of our existing shareholders are participating in a capital raising which will include funding to continue and expand on these programs,” said chairman, Patrick Holywell.

Immutep (ASX:IMM) +104% on news it is to start in early 2021 a phase two clinical trial for its metastatic breast cancer treatment. The trial is fully-funded by its Chinese partner, EOC Pharma, and will involve 152 patients in China.

The trial is expected to take 24 months to complete, and will evaluate Immutep’s lead product eftilagimod alpha in combination with paclitaxel in metastatic breast cancer patients.

“Breast cancer is now the most common cancer in Chinese women, with more than 1.6 million people being diagnosed and 1.2 million people dying of the disease each year,” EOC Pharma chief executive, Xiaoming Zou, said.

DorsaVi (ASX:DVL) +85% as the motion analysis device tech firm signed an agreement with Medtronic, one of the largest medical technology companies.

The Dublin, Ireland-based Medtronic is to evaluate DorsaVi’s technology for patients undergoing surgical evaluation in a 6 to 12-month review.

“This partnership aims to capture novel insights that we are confident will help Medtronic achieve better clinical evaluations for patients,” chief executive, Dr Andrew Ronchi, said.

DorsaVi’s wearable sensor technology can be used to capture data on human movement and has clinical and workplace applications.

Here are the best performing ASX small cap stocks for December 7 – December 11 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

ASX SMALL CAP LOSERS

Kaili Resources (ASX:KLR) -35% despite not making any public announcement since its December 3 drilling results statement for its Gindalbie gold project in WA.

The update then included some drilling results for Gindalbie in WA’s Yilgarn Craton, that included a hit of 1m at 1.08 grams per tonne gold from 49m.

The National Stock Exchange of Australia (ASX:NSX) -34% and with only a little news this week on a change to a director’s interest.

The NSX is focused on providing access to capital to venture and emerging companies and is targeting the digitisation of trading in fungible and non-fungible assets.

The tier-one securities exchange has a market capitalisation of $2.2bn, and lists 60 securities, and has links with 10 brokers. It joined the ASX and Chi-X platforms as a cleared equities market in November.

Here are the worst performing ASX small cap stocks for December 7 – December 11 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort: